Antibody Therapeutics for Life

Notices

PharmAbcine`s ``BI(Business Incubation) Research Grant`` proposal is granted by KIAT.
  • Written by Admin
  • Written date 2019-01-14 11:27:47
  • Inquire 80247

PharmAbcine`s "BI(Business Incubation) Research Grant" proposal is granted by KIAT (https://www.kiat.or.kr/site/main/main.jsp) and PharmAbcine will 

use this research funding to generate the second generation of PMC-001(DIG-KT) to get ready to out-license. The first generation version of PMC-001(DIG-KT) has been out-licensed to 3SBio for both Korea and China market in 2015.The CEO and CFO of PharmAbcine are going to participate the BI Research Grant workshop organized by KIAT and will have 1-to 1 partnering meetings with investors and business partners on July 13-14, 2017.

 

 

Reference:

 

http://www.prnewswire.com/news-releases/3sbio-signs-exclusive-patent-license-agreement-for-dig-kt-a-bi-specific-mab-targeting-vegfr2-and-tie-2-with-pharmabcine-300020495.html

 

http://bciq.biocentury.com/products/dig-kt

 

http://whosaeng.com/sub_read.html?uid=71563

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499296/

 

http://eng.kddf.org/bbs/bbs.asp?mode=view&IDX=717&p=1&cateId=35

 

http://www.worldbil.com/CTIP2015/Download/8.pdf

List





Prev Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present for ``Investor Relatio...
Next Dr. Lawrence Cher at Olivia Newton-Johns Cancer Wellness & Research Center/Austi...